Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ Niastase®) in the Treatment of Bleeding in Severely Injured Trauma Subjects

NCT01563523 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01563523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01563523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ Niastase®) in the Treatment of Bleeding in Severely Injured Trauma Subjects
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2002
Completion date
October 31, 2003
Enrollment
283 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bleeding disorder, trauma